CD3 Labs

The annual accounts of CD3 Labs for financial year 2025 show a net loss of 85% of the equity at the start of that year. The 2025 annual accounts show equity of €21,267 and a net result of -€118,898. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 15% of 239 sector peers (NACE 72, financial year 2025). The association has been active since 2007 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is below 0.1% (very low).